Brief: Vivos Therapeutics Receives FDA Clearance Of Its DNA Oral Appliance For Treatment Of Obstructive Sleep Apnea
04/01/2023 12:38
Jan 4 (Reuters) - Vivos Therapeutics Inc VVOS.O :
* VIVOS THERAPEUTICS RECEIVES FDA 510(K) CLEARANCE OF ITS
FLAGSHIP
DNA ORAL APPLIANCE FOR TREATMENT OF OBSTRUCTIVE SLEEP APNEA
Source text for Eikon: ID:nGNXc4b7Gw
Further company coverage: VVOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vivos Therapeutics
See all newsBrief: Vivos Therapeutics Closes Acquisition Of Stake In Sod Sciences And 50% Interest In Pseudohypoxia Test, Opening A Potential Path To Access More Than 325,000 New Patients Through The Aha Channel
Brief: Vivos Therapeutics - Audit Reports For Fy2025 And Fy2024 Include Substantial Doubt About Going Concern
Brief: Vivos Therapeutics And South Palm Cardiovascular Associates Sign Definitive Agreements To Launch Regional Sleep Testing And Treatment Center
Vivos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Vivos Therapeutics Q2 revenue rises 35% on service growth